Fig. 1.

SPRY2 is strongly expressed in GBM and its expression correlates with reduced overall survival in GBM patients. (A) The mRNA expression of 4 different SPRYs (SPRY1-4) in 3 GBM datasets using the R2 genomics analysis and visualization platform (http://r2.amc.nl). (B) SPRY2 expression levels in GBM compared with that of nontumor samples. TCGA and GSE4290 datasets, including P-values, were analyzed using ONCOMINE. (C) Levels of endogenous SPRY2 protein in normal human astrocyte (HA), U87 and GBM stemlike cells (GSC1 and GSC2) as determined by immunoblot. (D) Overall survival differences among GBM patients are shown as Kaplan‒Meier survival curve with high and low mRNA expression of SPRY2 from TCGA dataset. ***P < 0.001 by the log-rank test.